1
|
Stefaniak-Napieralska M, Walczyński K, Iwan M, Korga-Plewko A, Szałaj N, Więckowska A, Staszewski M. Preliminary studies of 1,5-benzoxazepine derivatives as potential histamine H 3 receptor antagonists. Future Med Chem 2024; 16:197-204. [PMID: 38189171 DOI: 10.4155/fmc-2023-0277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Accepted: 12/21/2023] [Indexed: 01/09/2024] Open
Abstract
Aims: Our research aimed to evaluate how the rigidification of the characteristic 3-aminopropyloxy linker by incorporating it into 1,5-benzoxazepines affects the potency of histamine H3 receptor (H3R) antagonists/inverse agonists. This research constitutes a starting point for the full characterization of the pharmacological properties of this group of compounds. Materials & methods: Several 1,5-benzoxazepine derivatives were synthesized and pharmacologically tested as potential H3R antagonist/inverse agonists. In a addition, the effect of the derivatives on acetylcholinesterase and butyrylcholinesterase inhibition and cytotoxicity were tested. Results: The studies indicated 1,5-benzoxazepine containing three carbon side chains as a compound for further modification. Conclusion: Further optimization of the lead structure is necessary, which will favorably affect biological targets.
Collapse
Affiliation(s)
| | - Krzysztof Walczyński
- Department of Synthesis & Technology of Drugs, Medical University of Lodz, Muszyńskiego 1, 90-151 Łódź, Poland
| | - Magdalena Iwan
- Department of Toxicology, Medical University of Lublin, Chodźki 8, 20-093 Lublin, Poland
| | - Agnieszka Korga-Plewko
- Independent Medical Biology Unit, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland
| | - Natalia Szałaj
- Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Anna Więckowska
- Department of Physicochemical Drug Analysis, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Marek Staszewski
- Department of Synthesis & Technology of Drugs, Medical University of Lodz, Muszyńskiego 1, 90-151 Łódź, Poland
| |
Collapse
|
2
|
Savych VI, Mykhalchuk VL, Melnychuk PV, Isakov AO, Savchuk T, Timoshenko VM, Siry SA, Pavlenko SO, Kovalenko DV, Hryshchuk OV, Reznik VA, Chalyk BA, Yarmolchuk VS, Rusanov EB, Mykhailiuk PK. Bicyclic Pyrrolidines for Medicinal Chemistry via [3 + 2]-Cycloaddition. J Org Chem 2021; 86:13289-13309. [PMID: 34428062 DOI: 10.1021/acs.joc.1c01327] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A general approach to bicyclic fused pyrrolidines via [3 + 2]-cycloaddition between nonstabilized azomethyne ylide and endocyclic electron-deficient alkenes was elaborated. "Push-pull" alkenes and CF3-alkenes did not react with the azomethyne ylide under the previously reported conditions, and we developed a superior protocol (LiF, 140 °C, no solvent). Among obtained products were medchem-relevant bicyclic sulfones, monofluoro-, difluoro-, and trifluoromethyl-substituted pyrrolidines. This approach not only allowed preparation of novel molecules but also significantly simplified synthesis of the existing ones (e.g., sofinicline).
Collapse
Affiliation(s)
- Vladimir I Savych
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | | | - Pavlo V Melnychuk
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | - Andrii O Isakov
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | - Taras Savchuk
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | - Vadim M Timoshenko
- Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Murmanska St. 5, 02094 Kyiv, Ukraine
| | - Sergiy A Siry
- Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Murmanska St. 5, 02094 Kyiv, Ukraine
| | - Sergiy O Pavlenko
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | | | | | - Vitalii A Reznik
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net
| | - Bohdan A Chalyk
- Enamine Ltd.; Chervonotkatska 78, 02094 Kyiv, Ukraine, www.enamine.net.,Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Murmanska St. 5, 02094 Kyiv, Ukraine
| | | | - Eduard B Rusanov
- Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Murmanska St. 5, 02094 Kyiv, Ukraine
| | | |
Collapse
|
3
|
Staszewski M, Nelic D, Jończyk J, Dubiel M, Frank A, Stark H, Bajda M, Jakubik J, Walczyński K. Guanidine Derivatives: How Simple Structural Modification of Histamine H 3R Antagonists Has Led to the Discovery of Potent Muscarinic M 2R/M 4R Antagonists. ACS Chem Neurosci 2021; 12:2503-2519. [PMID: 34100603 PMCID: PMC8291587 DOI: 10.1021/acschemneuro.1c00237] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
![]()
This article describes
the discovery of novel potent muscarinic
receptor antagonists identified during a search for more active histamine
H3 receptor (H3R) ligands. The idea was to replace
the flexible seven methylene linker with a semirigid 1,4-cyclohexylene
or p-phenylene substituted group of the previously
described histamine H3R antagonists ADS1017 and ADS1020. These simple structural modifications
of the histamine H3R antagonist led to the emergence of
additional pharmacological effects, some of which unexpectedly showed
strong antagonist potency at muscarinic receptors. This paper reports
the routes of synthesis and pharmacological characterization of guanidine
derivatives, a novel chemotype of muscarinic receptor antagonists
binding to the human muscarinic M2 and M4 receptors
(hM2R and hM4R, respectively) in nanomolar concentration
ranges. The affinities of the newly synthesized ADS10227 (1-{4-{4-{[4-(phenoxymethyl)cyclohexyl]methyl}piperazin-1-yl}but-1-yl}-1-(benzyl)guanidine)
at hM2R and hM4R were 2.8 nM and 5.1 nM, respectively.
Collapse
Affiliation(s)
- Marek Staszewski
- Department of Synthesis and Technology of Drugs, Medical University of Lodz, ul. Muszyńskiego 1, 90-151 Łódź, Poland
| | - Dominik Nelic
- Department of Neurochemistry, Institute of Physiology CAS, Videnska 1083, CZ142 20, Prague, Czech Republic
| | - Jakub Jończyk
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Mariam Dubiel
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, Duesseldorf 40225, Germany
| | - Annika Frank
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, Duesseldorf 40225, Germany
| | - Holger Stark
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, Duesseldorf 40225, Germany
| | - Marek Bajda
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Jan Jakubik
- Department of Neurochemistry, Institute of Physiology CAS, Videnska 1083, CZ142 20, Prague, Czech Republic
| | - Krzysztof Walczyński
- Department of Synthesis and Technology of Drugs, Medical University of Lodz, ul. Muszyńskiego 1, 90-151 Łódź, Poland
| |
Collapse
|
4
|
Kourounakis AP, Xanthopoulos D, Tzara A. Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules. Med Res Rev 2019; 40:709-752. [PMID: 31512284 DOI: 10.1002/med.21634] [Citation(s) in RCA: 111] [Impact Index Per Article: 22.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2019] [Revised: 07/22/2019] [Accepted: 08/21/2019] [Indexed: 12/15/2022]
Abstract
Morpholine is a heterocycle featured in numerous approved and experimental drugs as well as bioactive molecules. It is often employed in the field of medicinal chemistry for its advantageous physicochemical, biological, and metabolic properties, as well as its facile synthetic routes. The morpholine ring is a versatile and readily accessible synthetic building block, it is easily introduced as an amine reagent or can be built according to a variety of available synthetic methodologies. This versatile scaffold, appropriately substituted, possesses a wide range of biological activities. There are many examples of molecular targets of morpholine bioactive in which the significant contribution of the morpholine moiety has been demonstrated; it is an integral component of the pharmacophore for certain enzyme active-site inhibitors whereas it bestows selective affinity for a wide range of receptors. A large body of in vivo studies has demonstrated morpholine's potential to not only increase potency but also provide compounds with desirable drug-like properties and improved pharamacokinetics. In this review we describe the medicinal chemistry/pharmacological activity of morpholine derivatives on various therapeutically related molecular targets, attempting to highlight the importance of the morpholine ring in drug design and development as well as to justify its classification as a privileged structure.
Collapse
Affiliation(s)
- Angeliki P Kourounakis
- Department of Medicinal Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
| | - Dimitrios Xanthopoulos
- Department of Medicinal Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
| | - Ariadni Tzara
- Department of Medicinal Chemistry, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
5
|
Frank A, Meza-Arriagada F, Salas CO, Espinosa-Bustos C, Stark H. Nature-inspired pyrrolo[2,3-d]pyrimidines targeting the histamine H 3 receptor. Bioorg Med Chem 2019; 27:3194-3200. [PMID: 31176569 DOI: 10.1016/j.bmc.2019.05.042] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Revised: 04/05/2019] [Accepted: 05/28/2019] [Indexed: 01/22/2023]
Abstract
Inspired by marine compounds the derivatization of the natural pyrrolo[2,3-d]pyrimidine lead scaffold led to a series of novel compounds targeting the histamine H3 receptor. The focus was set on improved binding towards the receptor and to establish an initial structure-activity relationship for this compound class based on the lead structure (compound V, Ki value of 126 nM). As highest binding affinities were found with 1,4-bipiperidines as basic part of the ligands, further optimization was focused on 4-([1,4'-bipiperidin]-1'-yl)-pyrrolo[2,3-d]pyrimidines. Related pyrrolo[2,3-d]pyrimidines that were isolated from marine sponges like 4-amino-5-bromopyrrolo[2,3-d]pyrimidine (compound III), showed variations in halogenation pattern, though in a next step the impact of halogenation at 2-position was evaluated. The chloro variations did not improve the affinity compared to the dehalogenated compounds. However, the simultaneous introduction of lipophilic cores with electron-withdrawing substitution patterns in 7-position and dehalogenation at 2-position (11b, 12b) resulted in compounds with significantly higher binding affinities (Ki values of 7 nM and 6 nM, respectively) than the initial lead structure compound V. The presented structures allow for a reasonable structure-activity relationship of pyrrolo[2,3-d]pyrimidines as histamine H3 receptor ligands and yielded novel lead structures within the natural compound library against this target.
Collapse
Affiliation(s)
- Annika Frank
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, 40225 Duesseldorf, Germany
| | - Francisco Meza-Arriagada
- Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 6094411, Chile
| | - Cristian O Salas
- Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 6094411, Chile
| | - Christian Espinosa-Bustos
- Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 6094411, Chile.
| | - Holger Stark
- Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, 40225 Duesseldorf, Germany.
| |
Collapse
|
6
|
Lapa GB, Lapa AA. Synthesis and biological evaluation of new N-substituted 4-(arylmethoxy)piperidines as dopamine transporter inhibitors. MENDELEEV COMMUNICATIONS 2019. [DOI: 10.1016/j.mencom.2019.03.030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
7
|
Nirogi R, Shinde A, Mohammed AR, Badange RK, Reballi V, Bandyala TR, Saraf SK, Bojja K, Manchineella S, Achanta PK, Kandukuri KK, Subramanian R, Benade V, Palacharla RC, Jayarajan P, Pandey S, Jasti V. Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H 3 Receptor Inverse Agonist with Robust Wake-Promoting Activity. J Med Chem 2019; 62:1203-1217. [PMID: 30629436 DOI: 10.1021/acs.jmedchem.8b01280] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
A series of chemical optimizations guided by in vitro affinity at a histamine H3 receptor (H3R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake-promoting effects with decreased rapid-eye-movement sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety studies in animals have been successfully completed without any concern for further development.
Collapse
Affiliation(s)
- Ramakrishna Nirogi
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Anil Shinde
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Abdul Rasheed Mohammed
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Rajesh Kumar Badange
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Veena Reballi
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Thrinath Reddy Bandyala
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Sangram Keshari Saraf
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Kumar Bojja
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Sravanthi Manchineella
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Pramod Kumar Achanta
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Kiran Kumar Kandukuri
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Ramkumar Subramanian
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Vijay Benade
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Raghava Choudary Palacharla
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Pradeep Jayarajan
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Santoshkumar Pandey
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| | - Venkat Jasti
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7 , Banjara Hills, Hyderabad 500 034 , India
| |
Collapse
|
8
|
Correa MF, Dos Santos Fernandes JP. QSAR Modeling of Histamine H3R Antagonists/inverse Agonists as Future Drugs for Neurodegenerative Diseases. Curr Neuropharmacol 2018; 16:749-757. [PMID: 28820054 PMCID: PMC6080103 DOI: 10.2174/1570159x15666170818100644] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Revised: 07/04/2017] [Accepted: 08/16/2017] [Indexed: 11/22/2022] Open
Abstract
Background Histamine H3 receptor (H3R) is associated with several neuropsychological diseases, and thus it is an important target involved in several CNS disorders, such as narcolepsy, attention deficit hyperactivity disorder and schizophrenia. Since QSAR modeling is a feasible approach to explain the role of the molecular substituents in the biological activity, it can help in improving the design of better H3R ligands for these conditions. Methods This article reviews papers previously published in literature to show the current status of the contribution from QSAR modeling to reach H3R antagonists/inverse agonists. Results Classical and 3D-QSAR models were retrieved, showing that the steric and hydrophobic properties of the H3R ligands are most important to reach good affinity. Conclusion Although QSAR methods are valuable to design better H3R antagonists/inverse agonists, pharmacokinetics should also be considered in future models to ensure good CNS penetration.
Collapse
Affiliation(s)
- Michelle Fidelis Correa
- Departamento de Ciencias Farmaceuticas, Universidade Federal de Sao Paulo, Rua Sao Nicolau 210, Centro 09913- 030, Diadema-SP, Brazil
| | - Joao Paulo Dos Santos Fernandes
- Departamento de Ciencias Farmaceuticas, Universidade Federal de Sao Paulo, Rua Sao Nicolau 210, Centro 09913- 030, Diadema-SP, Brazil
| |
Collapse
|
9
|
Espinosa-Bustos C, Frank A, Arancibia-Opazo S, Salas CO, Fierro A, Stark H. New lead elements for histamine H3 receptor ligands in the pyrrolo[2,3-d]pyrimidine class. Bioorg Med Chem Lett 2018; 28:2890-2893. [DOI: 10.1016/j.bmcl.2018.07.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Revised: 07/11/2018] [Accepted: 07/12/2018] [Indexed: 11/29/2022]
|
10
|
Olszewska B, Stasiak A, McNaught Flores D, Fogel WA, Leurs R, Walczyński K. 4-Hydroxypiperidines and Their Flexible 3-(Amino)propyloxy Analogues as Non-Imidazole Histamine H₃ Receptor Antagonist: Further Structure⁻Activity Relationship Exploration and In Vitro and In Vivo Pharmacological Evaluation. Int J Mol Sci 2018; 19:ijms19041243. [PMID: 29671795 PMCID: PMC5979327 DOI: 10.3390/ijms19041243] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2018] [Revised: 04/05/2018] [Accepted: 04/17/2018] [Indexed: 11/30/2022] Open
Abstract
Presynaptic histamine H3 receptors (H3R) act as auto- or heteroreceptors controlling, respectively, the release of histamine and of other neurotransmitters in the central nervous system (CNS). The extracellular levels of several neurotransmitters are enhanced by H3R antagonists, and there is a great interest for potent, brain-penetrating H3 receptor antagonists/inverse agonists to compensate for the neurotransmitter deficits present in various neurological disorders. We have shown that 1-[(benzylfuran-2-yl)methyl]piperidinyl-4-oxyl- and benzyl- derivatives of N-propylpentan-1-amines exhibit high in vitro potencies toward the guinea pig H3 receptor (jejunum), with pA2 = 8.47 and 7.79, respectively (the reference compound used was thioperamide with pA2 = 8.67). Furthermore, following the replacement of 4-hydroxypiperidine with a 3-(methylamino)propyloxy chain, the pA2 value for the first group decreased, whereas it increased for the second group. Here, we present data on the impact of elongating the aliphatic chain between the nitrogen of 4-hydroxypiperidine or 3-(methylamino)propan-1-ol and the lipophilic residue. Additionally, the most active compound in this series of non-imidazole H3 receptor antagonists/inverse agonists, i.e., ADS-003, was evaluated for its affinity to the recombinant rat and human histamine H3 receptors transiently expressed in HEK-293T cells. It was shown that ADS-003, given parenterally for 5 days, reduced the food intake of rats, as well as changed histamine and noradrenaline concentrations in the rats’ brain in a manner and degree similar to the reference H3 antagonist Ciproxifan.
Collapse
Affiliation(s)
- Beata Olszewska
- Department of Synthesis and Technology of Drugs, Medical University of Lodz, Muszyńskiego Street 1, 90-145 Łódź, Poland.
| | - Anna Stasiak
- Department of Hormone Biochemistry, Medical University of Lodz, Żeligowskiego Street 7/9, 90-752 Łódź, Poland.
| | - Daniel McNaught Flores
- Amsterdam Institute of Molecules, Medicines & Systems, Division of Medicinal Chemistry, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands.
| | - Wiesława Agnieszka Fogel
- Department of Hormone Biochemistry, Medical University of Lodz, Żeligowskiego Street 7/9, 90-752 Łódź, Poland.
| | - Rob Leurs
- Amsterdam Institute of Molecules, Medicines & Systems, Division of Medicinal Chemistry, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands.
| | - Krzysztof Walczyński
- Department of Synthesis and Technology of Drugs, Medical University of Lodz, Muszyńskiego Street 1, 90-145 Łódź, Poland.
| |
Collapse
|
11
|
Hauwert NJ, Mocking TAM, Da Costa Pereira D, Kooistra AJ, Wijnen LM, Vreeker GCM, Verweij EWE, De Boer AH, Smit MJ, De Graaf C, Vischer HF, de Esch IJP, Wijtmans M, Leurs R. Synthesis and Characterization of a Bidirectional Photoswitchable Antagonist Toolbox for Real-Time GPCR Photopharmacology. J Am Chem Soc 2018; 140:4232-4243. [PMID: 29470065 PMCID: PMC5879491 DOI: 10.1021/jacs.7b11422] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
![]()
Noninvasive methods
to modulate G protein-coupled receptors (GPCRs)
with temporal and spatial precision are in great demand. Photopharmacology
uses photons to control in situ the biological properties
of photoswitchable small-molecule ligands, which bodes well for chemical
biological precision approaches. Integrating the light-switchable
configurational properties of an azobenzene into the ligand core,
we developed a bidirectional antagonist toolbox for an archetypical
family A GPCR, the histamine H3 receptor (H3R). From 16 newly synthesized photoswitchable compounds, VUF14738
(28) and VUF14862 (33) were selected as
they swiftly and reversibly photoisomerize and show over 10-fold increased
or decreased H3R binding affinities, respectively, upon
illumination at 360 nm. Both ligands combine long thermal half-lives
with fast and high photochemical trans-/cis conversion, allowing their use in real-time electrophysiology experiments
with oocytes to confirm dynamic photomodulation of H3R
activation in repeated second-scale cycles. VUF14738 and VUF14862
are robust and fatigue-resistant photoswitchable GPCR antagonists
suitable for spatiotemporal studies of H3R signaling.
Collapse
Affiliation(s)
- Niels J Hauwert
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Tamara A M Mocking
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Daniel Da Costa Pereira
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Albert J Kooistra
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Lisa M Wijnen
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Gerda C M Vreeker
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Eléonore W E Verweij
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Albertus H De Boer
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Martine J Smit
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Chris De Graaf
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Henry F Vischer
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Iwan J P de Esch
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Maikel Wijtmans
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| | - Rob Leurs
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Faculty of Science , Vrije Universiteit Amsterdam , De Boelelaan 1108 , 1081 HZ Amsterdam , The Netherlands
| |
Collapse
|
12
|
Wilhelmsen CA, Dixon ADC, Chisholm JD, Clark DA. Synthesis of N-Substituted 3-Amino-4-halopyridines: A Sequential Boc-Removal/Reductive Amination Mediated by Brønsted and Lewis Acids. J Org Chem 2018; 83:1634-1642. [PMID: 29308898 DOI: 10.1021/acs.joc.7b02966] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
N-Substituted 3-amino-4-halopyridines are valuable synthetic intermediates, as they readily provide access to imidazopyridines and similar heterocyclic systems. The direct synthesis of N-substituted 3-amino-4-halopyridines is problematic, as reductive aminations and base-promoted alkylations are difficult in these systems. A high yielding deprotection/alkylation protocol mediated by trifluoroacetic acid and trimethylsilyl trifluoromethanesulfonate is described, providing access to a wide scope of N-substituted 3-amino-4-halopyridines. This protocol furnishes many reaction products in high purity without chromatography. Similar reductive amination conditions were also established for deactivated anilines.
Collapse
Affiliation(s)
- Christopher A Wilhelmsen
- Department of Chemistry, 1-014 Center for Science and Technology, Syracuse University , Syracuse, New York 13244, United States
| | - Alexandre D C Dixon
- Department of Chemistry, 1-014 Center for Science and Technology, Syracuse University , Syracuse, New York 13244, United States
| | - John D Chisholm
- Department of Chemistry, 1-014 Center for Science and Technology, Syracuse University , Syracuse, New York 13244, United States
| | - Daniel A Clark
- Department of Chemistry, 1-014 Center for Science and Technology, Syracuse University , Syracuse, New York 13244, United States
| |
Collapse
|
13
|
Al-Alshaikh MA, Mary Y S, Panicker CY, Attia MI, El-Emam AA, Alsenoy CV. Spectroscopic investigations and molecular docking study of 3-(1H-imidazol-1-yl)-1-phenylpropan-1-one, a potential precursor to bioactive agents. J Mol Struct 2016. [DOI: 10.1016/j.molstruc.2015.12.075] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Nikolic K, Agbaba D, Stark H. Pharmacophore modeling, drug design and virtual screening on multi-targeting procognitive agents approaching histaminergic pathways. J Taiwan Inst Chem Eng 2015. [DOI: 10.1016/j.jtice.2014.09.017] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
15
|
Lepailleur A, Freret T, Lemaître S, Boulouard M, Dauphin F, Hinschberger A, Dulin F, Lesnard A, Bureau R, Rault S. Dual histamine H3R/serotonin 5-HT4R ligands with antiamnesic properties: pharmacophore-based virtual screening and polypharmacology. J Chem Inf Model 2014; 54:1773-84. [PMID: 24857631 DOI: 10.1021/ci500157n] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
In recent years, preclinical and clinical studies have generated considerable interest in the development of histamine H3 receptor (H3R) antagonists as novel treatment for degenerative disorders associated with impaired cholinergic function. To identify novel scaffolds for H3R antagonism, a common feature-based pharmacophore model was developed and used to screen the 17,194 compounds of the CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) chemical library. Out of 268 virtual hits which have been gathered in 34 clusters, we were particularly interested in tricyclic derivatives also exhibiting a potent 5HT4R affinity. Benzo[h][1,6]naphthyridine derivatives showed the highest H3R affinity, and compound 17 (H3R Ki = 41.6 nM; 5-HT4R Ki = 208 nM) completely reversed the amnesiant effect of scopolamine at 3 mg/kg in a spatial working memory experiment. For the first time we demonstrated the feasibility to combine H3R and 5-HT4R activities in a single molecule, raising the exciting possibility that dual H3R antagonist/5HT4R agonist have potential for the treatment of neurodegenerative diseases such as Alzheimer's disease.
Collapse
|
16
|
Wingen K, Schwed JS, Isensee K, Weizel L, Zivković A, Odadzic D, Odazic D, Stark H. Benzylpiperidine variations on histamine H3 receptor ligands for improved drug-likeness. Bioorg Med Chem Lett 2014; 24:2236-9. [PMID: 24745967 DOI: 10.1016/j.bmcl.2014.03.098] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Revised: 03/27/2014] [Accepted: 03/28/2014] [Indexed: 12/20/2022]
Abstract
Several hH3R antagonists/inverse agonists entered clinical phases for a broad spectrum of mainly centrally occurring diseases. Nevertheless, many promising candidates failed due to their pharmacokinetic profile, mostly because of their strong lipophilicity and their dibasic character. Analysis of previously, as potential PET ligands synthesized compounds (ST-889, ST-928) revealed promising results concerning physicochemical properties and drug-likeness. Herein, the synthesis, the evaluation of the binding properties at the hH3R and the estimation of different physicochemical and drug-likeness properties of further novel benzylpiperidine variations on H3R antagonists is described. Due to the introduction of various small hydrophilic moieties in the structure, drug-likeness parameters have been improved. For instance, compound 12 (ST-1032) showed in addition to high affinity at the H3R (pKi (hH3R)=9.3) clogS, clogP, LE, LipE, and LELP values of -2.48, 2.18, 0.44, 7.14, and 4.95, respectively. Also, the keto derivative 5 (ST-1703, pKi (hH3R)=8.6) revealed LipE and LELP values of 5.25 and 6.84, respectively.
Collapse
Affiliation(s)
- Kerstin Wingen
- Johann Wolfgang Goethe University, Institute of Pharmaceutical Chemistry, Biozentrum, Max-von-Laue-Str. 9, 60438 Frankfurt/Main, Germany
| | - J Stephan Schwed
- Heinrich Heine University Duesseldorf, Institute of Pharmaceutical and Medicinal Chemistry, Universitaetsstr. 1, 40225 Duesseldorf, Germany
| | - Kathleen Isensee
- Johann Wolfgang Goethe University, Institute of Pharmaceutical Chemistry, Biozentrum, Max-von-Laue-Str. 9, 60438 Frankfurt/Main, Germany
| | - Lilia Weizel
- Johann Wolfgang Goethe University, Institute of Pharmaceutical Chemistry, Biozentrum, Max-von-Laue-Str. 9, 60438 Frankfurt/Main, Germany
| | - Aleksandra Zivković
- Heinrich Heine University Duesseldorf, Institute of Pharmaceutical and Medicinal Chemistry, Universitaetsstr. 1, 40225 Duesseldorf, Germany
| | | | - Dalibor Odazic
- Johann Wolfgang Goethe University, Institute of Pharmaceutical Chemistry, Biozentrum, Max-von-Laue-Str. 9, 60438 Frankfurt/Main, Germany
| | - Holger Stark
- Heinrich Heine University Duesseldorf, Institute of Pharmaceutical and Medicinal Chemistry, Universitaetsstr. 1, 40225 Duesseldorf, Germany.
| |
Collapse
|
17
|
Brown DG, Bernstein PR, Griffin A, Wesolowski S, Labrecque D, Tremblay MC, Sylvester M, Mauger R, Edwards PD, Throner SR, Folmer JJ, Cacciola J, Scott C, Lazor LA, Pourashraf M, Santhakumar V, Potts WM, Sydserff S, Giguère P, Lévesque C, Dasser M, Groblewski T. Discovery of Spirofused Piperazine and Diazepane Amides as Selective Histamine-3 Antagonists with in Vivo Efficacy in a Mouse Model of Cognition. J Med Chem 2014; 57:733-58. [DOI: 10.1021/jm4014828] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Dean G. Brown
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Peter R. Bernstein
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Andrew Griffin
- AstraZeneca Montréal, 7171
Frédérick-Banting, Montréal, Québec H4S 1Z9, Canada
| | - Steve Wesolowski
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Denis Labrecque
- AstraZeneca Montréal, 7171
Frédérick-Banting, Montréal, Québec H4S 1Z9, Canada
| | - Maxime C. Tremblay
- AstraZeneca Montréal, 7171
Frédérick-Banting, Montréal, Québec H4S 1Z9, Canada
| | - Mark Sylvester
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Russell Mauger
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Phillip D. Edwards
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Scott R. Throner
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - James J. Folmer
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Joseph Cacciola
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Clay Scott
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Lois A. Lazor
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Mehrnaz Pourashraf
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Vijayaratnam Santhakumar
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - William M. Potts
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Simon Sydserff
- AstraZeneca CNS Discovery Research, 1800 Concord Pike, Wilmington, Delaware 19850, United States
| | - Pascall Giguère
- OmegaChem, 480 Rue Perreault, Saint-Romuald, Québec G6W 7 V6, Canada
| | - Carine Lévesque
- OmegaChem, 480 Rue Perreault, Saint-Romuald, Québec G6W 7 V6, Canada
| | - Mohammed Dasser
- OmegaChem, 480 Rue Perreault, Saint-Romuald, Québec G6W 7 V6, Canada
| | - Thierry Groblewski
- AstraZeneca Montréal, 7171
Frédérick-Banting, Montréal, Québec H4S 1Z9, Canada
| |
Collapse
|
18
|
Masłowska-Lipowicz I, Walczyński K. Structure-activity relationships of new 1-substitutedmethyl-4-[5-(N-methyl-N-propylamino)pentyloxy]piperidines and selected 1-[(N-substituted-N-methyl)-3-propyloxy]-5-(N-methy-l-N-propyl)-pentanediamines as H3 -antagonists. Chem Biol Drug Des 2013; 83:106-18. [PMID: 23957330 DOI: 10.1111/cbdd.12206] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2013] [Revised: 06/14/2013] [Accepted: 08/12/2013] [Indexed: 11/27/2022]
Abstract
Novel, potent non-imidazole histamine H3 receptor antagonists have been prepared and in vitro tested as H3 -receptor antagonists (the electrically evoked contraction of the guinea-pig jejunum). The present compounds contain a 4-hydroxypiperidine core, which behaves as a conformationally restricted version of the 3-amino-1-propanol moiety common to the many previously described non-imidazole H3 ligands. Detailed structure-activity studies revealed that 1-(2-benzofuranylmethyl)- 5c (pA2 = 8.47 ± 0.05) and 1-(3-benzofuranylmethyl)-4-[5-(N-methyl-N-propyl)pentyloxy]piperidine 5d (pA2 = 8.15 ± 0.07) exhibit high potency for the H3 histamine receptor. In addition, the potency of selected 1-[(N-substituted-N-methyl)-3-propyloxy]-5-(N-methyl-N-propyl)pentanediamines as antagonist of the H3 histamine receptor was also evaluated. Replacement of the 4-hydroxypiperidine of the leads 7 and 5c by a highly flexible 3-(methylamino)propyloxy chain yields compounds 6a (pA2 = 8.02) and 6b (pA2 = 6.23) with higher and lower potency than their piperidine analogues (7, pA2 = 7.79; 5c, pA2 = 8.47), respectively. The histaminergic H1 antagonism of selected compounds 5c, 5d and 6a has been established on the isolated guinea-pig ileum by conventional methods; the pA2 values have compared with the potency of pyrilamine. None of them showed any H1 -antagonistic activity (pA2 < 4; for pyrilamine pA2 = 8.5).
Collapse
Affiliation(s)
- Iwona Masłowska-Lipowicz
- Department of Synthesis and Technology of Drugs, Medical University, Muszyńskiego Street 1, 90-151, Łódź, Poland
| | | |
Collapse
|
19
|
Dandu RR, Lyons JA, Raddatz R, Huang Z, Aimone LD, Hudkins RL. Synthesis and evaluation of a new series of 1′-cyclobutyl-6-(4-piperidyloxy)spiro[benzopyran-2,4′-piperidine] derivatives as high affinity and selective histamine-3 receptor (H3R) antagonists. Bioorg Med Chem Lett 2012; 22:2151-3. [DOI: 10.1016/j.bmcl.2012.01.139] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2011] [Revised: 01/30/2012] [Accepted: 01/31/2012] [Indexed: 11/24/2022]
|
20
|
Sundar BG, Bailey TR, Dunn D, Hostetler GA, Chatterjee S, Bacon ER, Yue C, Schweizer D, Aimone LD, Gruner JA, Lyons J, Raddatz R, Lesur B. Novel morpholine ketone analogs as potent histamine H3 receptor inverse agonists with wake activity. Bioorg Med Chem Lett 2012; 22:1546-9. [DOI: 10.1016/j.bmcl.2012.01.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2011] [Revised: 01/02/2012] [Accepted: 01/03/2012] [Indexed: 11/28/2022]
|
21
|
Hudkins RL, Zulli AL, Dandu RR, Tao M, Josef KA, Aimone LD, Haltiwanger RC, Huang Z, Lyons JA, Mathiasen JR, Raddatz R, Gruner JA. 4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activity. Bioorg Med Chem Lett 2012; 22:1504-9. [PMID: 22290075 DOI: 10.1016/j.bmcl.2012.01.026] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2011] [Revised: 01/04/2012] [Accepted: 01/09/2012] [Indexed: 11/25/2022]
Abstract
Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H(3)R antagonists/inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metabolites identified 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one 17b. Compound 17b met discovery flow criteria, demonstrated potent H(3)R functional antagonism in vivo in the rat dipsogenia model and potent wake activity in the rat EEG/EMG model at doses as low as 0.1 mg/kg ip.
Collapse
Affiliation(s)
- Robert L Hudkins
- Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Tao M, Aimone LD, Gruner JA, Mathiasen JR, Huang Z, Lyons J, Raddatz R, Hudkins RL. Synthesis and structure-activity relationship of 5-pyridazin-3-one phenoxypiperidines as potent, selective histamine H(3) receptor inverse agonists. Bioorg Med Chem Lett 2011; 22:1073-7. [PMID: 22197136 DOI: 10.1016/j.bmcl.2011.11.118] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2011] [Revised: 11/22/2011] [Accepted: 11/28/2011] [Indexed: 10/14/2022]
Abstract
Optimization of the R(2) and R(6) positions of (5-{4-[3-(R)-2-methylpyrrolin-1-yl-propoxy]phenyl}-2H-pyridazin-3-one) 2a with constrained phenoxypiperidines led to the identification of 5-[4-(cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2H-pyridazin-3-one 8b as a potent, selective histamine H(3) receptor antagonist with favorable pharmacokinetic properties. Compound 8b had an excellent safety genotoxocity profile for a CNS-active compound in the Ames and micronucleus tests, also displayed potent H(3)R antagonist activity in the brain in the rat dipsogenia model and robust wake activity in the rat EEG/EMG model.
Collapse
Affiliation(s)
- Ming Tao
- Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists. Bioorg Med Chem Lett 2011; 21:7076-80. [DOI: 10.1016/j.bmcl.2011.09.091] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2011] [Revised: 09/19/2011] [Accepted: 09/21/2011] [Indexed: 11/18/2022]
|
24
|
Zhou D, Gross JL, Sze JY, Adedoyin AB, Bowlby M, Di L, Platt BJ, Zhang G, Brandon N, Comery TA, Robichaud AJ. Pyrrolidin-3-yl-N-methylbenzamides as potent histamine 3 receptor antagonists. Bioorg Med Chem Lett 2011; 21:5957-60. [PMID: 21843941 DOI: 10.1016/j.bmcl.2011.07.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2011] [Revised: 07/16/2011] [Accepted: 07/19/2011] [Indexed: 11/15/2022]
Abstract
On the basis of the previously reported benzimidazole 1,3'-bipyrrolidine benzamides (1), a series of related pyrrolidin-3-yl-N-methylbenzamides were synthesized and evaluated as H(3) receptor antagonists. In particular, compound 32 exhibits potent H(3) receptor binding affinity, improved pharmaceutical properties and a favorable in vivo profile.
Collapse
Affiliation(s)
- Dahui Zhou
- Pfizer Global Research and Development, 445 Eastern Point Road, Groton, CT 06340, United States.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Berlin M, Boyce CW, de Lera Ruiz M. Histamine H3 Receptor as a Drug Discovery Target. J Med Chem 2010; 54:26-53. [DOI: 10.1021/jm100064d] [Citation(s) in RCA: 117] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Michael Berlin
- Chemical Research, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Christopher W. Boyce
- Chemical Research, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Manuel de Lera Ruiz
- Chemical Research, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
26
|
Investigation of 4-piperidinols as novel H3 antagonists. Bioorg Med Chem Lett 2010; 20:6246-9. [DOI: 10.1016/j.bmcl.2010.08.099] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2010] [Revised: 08/18/2010] [Accepted: 08/19/2010] [Indexed: 11/21/2022]
|
27
|
Santillan A, McClure KJ, Allison BD, Lord B, Boggs JD, Morton KL, Everson AM, Nepomuceno D, Letavic MA, Lee-Dutra A, Lovenberg TW, Carruthers NI, Grice CA. Indole- and benzothiophene-based histamine H3 antagonists. Bioorg Med Chem Lett 2010; 20:6226-30. [DOI: 10.1016/j.bmcl.2010.08.103] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2010] [Revised: 08/19/2010] [Accepted: 08/20/2010] [Indexed: 10/19/2022]
|
28
|
A quantum chemical study on a set of non-imidazole H3 antihistamine molecules. J Mol Graph Model 2010; 28:657-63. [DOI: 10.1016/j.jmgm.2010.01.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2009] [Accepted: 01/09/2010] [Indexed: 10/20/2022]
|
29
|
Wijtmans M, Denonne F, Célanire S, Gillard M, Hulscher S, Delaunoy C, Van houtvin N, Bakker RA, Defays S, Gérard J, Grooters L, Hubert D, Timmerman H, Leurs R, Talaga P, de Esch IJP, Provins L. Histamine H3 receptor ligands with a 3-cyclobutoxy motif: a novel and versatile constraint of the classical 3-propoxy linker. MEDCHEMCOMM 2010. [DOI: 10.1039/c0md00056f] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
30
|
MALDI–tandem mass spectrometry imaging of astemizole and its primary metabolite in rat brain sections. Bioanalysis 2009; 1:299-307. [DOI: 10.4155/bio.09.27] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background: Matrix-assisted laser desorption/ionization (MALDI)–tandem mass spectrometry (MS)/MS is a proven reliable tool for visualizing the spatial distribution of dosed drugs and their primary metabolites in animal tissue sections. Materials & methods: The rat brain tissue sections coated with dihydroxybenzoic acid as matrix, were analyzed by MALDI–MS/MS imaging experiments. The potential metabolites of astemizole in rat brain homogenate selected for MALDI–MS/MS imaging experiments were first identified by high-performance liquid chromatography coupled to an electrospray ionization source and a hybrid-quadrupole–linear-ion-trap mass spectrometer. Results: Astemizole was observed to be heterogeneously distributed to most parts of the brain tissue slices including the cortex, hippocampus, hypothalamic, thalamus and ventricle regions, while its major metabolite, desmethylastemizole, was only found around ventricle sites. Conclusion: The results indicated that the dosed compound alone might be responsible for the CNS side-effects when drug exposures became elevated.
Collapse
|
31
|
Novel imidazole-based histamine H3 antagonists. Bioorg Med Chem Lett 2009; 19:903-7. [DOI: 10.1016/j.bmcl.2008.11.114] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2008] [Revised: 11/25/2008] [Accepted: 11/26/2008] [Indexed: 11/21/2022]
|
32
|
Sasho S, Seishi T, Kawamura M, Tomuro M, Hirose R, Toki S, Shimada J. Diamine Derivatives Containing Imidazolidinylidene Propanedinitrile as a New Class of Histamine H3 Receptor Antagonists: Conformationally Restricted Derivatives. Chem Pharm Bull (Tokyo) 2009; 57:288-93. [DOI: 10.1248/cpb.57.288] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Setsuya Sasho
- Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd
| | - Takashi Seishi
- Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd
| | - Mariko Kawamura
- Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd
| | - Misato Tomuro
- Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd
| | - Ryo Hirose
- Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd
| | - Shinichiro Toki
- Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd
| | - Junich Shimada
- Medicinal Chemistry Research Laboratories, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd
| |
Collapse
|
33
|
Maslowska-Lipowicz I, Figlus M, Zuiderveld OP, Walczynski K. New 1-benzyl-4-hydroxypiperidine derivatives as non-imidazole histamine H3 receptor antagonists. Arch Pharm (Weinheim) 2008; 341:762-73. [PMID: 19009544 DOI: 10.1002/ardp.200800070] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
A series of 1-benzyl-4-(3-aminopropyloxy)piperidine and 1-benzyl-4-(5-aminopentyloxy)piperidine derivatives has been prepared. The 1-benzyl-4-hydroxypiperidine derivatives obtained were evaluated for their affinities at recombinant human histamine H(3 )receptor, stably expressed in HEK 293T cells. All compounds investigated show moderate to pronounced in-vitro affinities. The most potent antagonists in this series 9b2 (hH(3)R, pK(i) = 7.09), 9b1 (hH(3)R, pK(i) = 6.78), 9b5 (hH(3)R, pK(i) = 6.99), and 9b6 (hH(3)R, pK(i )= 6.97) were also tested in vitro as H(3 )receptor antagonists - the electrically evoked contraction of the guinea-pig jejunum. The histaminergic H(1) antagonism of selected compounds 9b1, 9b2, and 9b4-9b6 was established on the isolated guinea-pig ileum by conventional methods; the pA(2) values were compared with the potency of pyrilamine. The compounds did not show any H(1) antagonistic activity (pA(2) < 4; for pyrilamine pA(2) = 9.53).
Collapse
|
34
|
Nagase T, Mizutani T, Sekino E, Ishikawa S, Ito S, Mitobe Y, Miyamoto Y, Yoshimoto R, Tanaka T, Ishihara A, Takenaga N, Tokita S, Sato N. Synthesis and Evaluation of Structurally Constrained Quinazolinone Derivatives as Potent and Selective Histamine H3 Receptor Inverse Agonists. J Med Chem 2008; 51:6889-901. [DOI: 10.1021/jm800569w] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Tsuyoshi Nagase
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Takashi Mizutani
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Etsuko Sekino
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Shiho Ishikawa
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Sayaka Ito
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Yuko Mitobe
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Yasuhisa Miyamoto
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Ryo Yoshimoto
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Takeshi Tanaka
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Akane Ishihara
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Norihiro Takenaga
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Shigeru Tokita
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| | - Nagaaki Sato
- Tsukuba Research Institute, Merck Research Laboratories, Banyu Pharmaceutical Co., Ltd., Okubo 3, Tsukuba 300-2611, Japan
| |
Collapse
|
35
|
Łażewska D, Kuder K, Ligneau X, Schwartz JC, Schunack W, Stark H, Kieć-Kononowicz K. Piperidine variations in search for non-imidazole histamine H3 receptor ligands. Bioorg Med Chem 2008; 16:8729-36. [DOI: 10.1016/j.bmc.2008.07.071] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2008] [Revised: 07/20/2008] [Accepted: 07/24/2008] [Indexed: 11/17/2022]
|
36
|
A new family of H3 receptor antagonists based on the natural product Conessine. Bioorg Med Chem Lett 2008; 18:1490-4. [DOI: 10.1016/j.bmcl.2007.12.059] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2007] [Revised: 12/17/2007] [Accepted: 12/21/2007] [Indexed: 11/20/2022]
|
37
|
Sander K, Kottke T, Stark H. Histamine H3 Receptor Antagonists Go to Clinics. Biol Pharm Bull 2008; 31:2163-81. [DOI: 10.1248/bpb.31.2163] [Citation(s) in RCA: 162] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Kerstin Sander
- Johann Wolfgang Goethe-Universität Frankfurt am Main, Institut für Pharmazeutische Chemie
| | - Tim Kottke
- Johann Wolfgang Goethe-Universität Frankfurt am Main, Institut für Pharmazeutische Chemie
| | - Holger Stark
- Johann Wolfgang Goethe-Universität Frankfurt am Main, Institut für Pharmazeutische Chemie
| |
Collapse
|
38
|
Procopiou PA, Ancliff RA, Bamford MJ, Browning C, Connor H, Davies S, Fogden YC, Hodgson ST, Holmes DS, Looker BE, Morriss KML, Parr CA, Pickup EA, Sehmi SS, White GV, Watts CJ, Wilson DM, Woodrow MD. 4-Acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a Novel Class of Non-Brain-Penetrant Histamine H3 Receptor Antagonists. J Med Chem 2007; 50:6706-17. [DOI: 10.1021/jm0708228] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Panayiotis A. Procopiou
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Rachael A. Ancliff
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Mark J. Bamford
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Christopher Browning
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Helen Connor
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Susannah Davies
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Yvonne C. Fogden
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Simon T. Hodgson
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Duncan S. Holmes
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Brian E. Looker
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Karen M. L. Morriss
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Christopher A. Parr
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Elizabeth A. Pickup
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Sanjeet S. Sehmi
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Gemma V. White
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Clarissa J. Watts
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - David M. Wilson
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| | - Michael D. Woodrow
- Departments of Chemistry, Pharmacology, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K., and GlaxoSmithKline New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW, U.K
| |
Collapse
|
39
|
Funaki Y, Sato K, Kato M, Ishikawa Y, Iwata R, Yanai K. Evaluation of the binding characteristics of [18F]fluoroproxyfan in the rat brain for in vivo visualization of histamine H3 receptor. Nucl Med Biol 2007; 34:981-7. [DOI: 10.1016/j.nucmedbio.2007.07.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2007] [Revised: 07/10/2007] [Accepted: 07/18/2007] [Indexed: 10/22/2022]
|
40
|
Letavic MA, Stocking EM, Barbier AJ, Bonaventure P, Boggs JD, Lord B, Miller KL, Wilson SJ, Carruthers NI. Benzylamine histamine H3 antagonists and serotonin reuptake inhibitors. Bioorg Med Chem Lett 2007; 17:4799-803. [PMID: 17616397 DOI: 10.1016/j.bmcl.2007.06.061] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2007] [Accepted: 06/18/2007] [Indexed: 11/15/2022]
Abstract
The design, synthesis, and in vitro activity of a series of novel 5-ethynyl-2-aryloxybenzylamine-based histamine H(3) ligands that are also serotonin reuptake transporters is described.
Collapse
Affiliation(s)
- Michael A Letavic
- Johnson & Johnson Pharmaceutical Research & Development LLC, 3210 Merryfield Row, San Diego, CA 92121, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Wijtmans M, Leurs R, de Esch I. Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Investig Drugs 2007; 16:967-85. [PMID: 17594183 DOI: 10.1517/13543784.16.7.967] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The neurotransmitter histamine exerts its action through four distinct histamine receptors. The histamine H(1) and H(2) receptor are well established drug targets, whereas the histamine H(4) receptor is undergoing rigorous characterisation at present. The histamine H(3) receptor (H(3)R) is a G(i/o)-protein coupled receptor and is mostly expressed in the CNS. A remarkably large and different array of therapeutic areas, in which ligands for the H(3)R may prove useful, has been identified and a massive research undertaking is underway to substantiate the high expectations for H(3)R ligands. At present, several ligands for the H(3)R are being evaluated in clinical studies. In this review, the many potential therapeutic areas for H(3)R antagonists, inverse agonists and agonists is discussed. Promising medicinal chemistry and toxicological developments, as well as the advancement of several H(3)R ligands into the clinic, will be highlighted. This review also describes the problems that have been overcome and the questions that remain in developing H(3)R-related drugs. Considering the tremendous efforts by industry, it can be expected that the first H(3)R drugs will reach the market soon.
Collapse
Affiliation(s)
- Maikel Wijtmans
- Vrije Universiteit Amsterdam, Leiden/Amsterdam Center of Drug Research, Division of Medicinal Chemistry, Faculty of Sciences, De Boelelaan 1083, Amsterdam, The Netherlands
| | | | | |
Collapse
|
42
|
Stocking EM, Miller JM, Barbier AJ, Wilson SJ, Boggs JD, McAllister HM, Wu J, Lovenberg TW, Carruthers NI, Wolin RL. Synthesis and biological evaluation of diamine-based histamine H3 antagonists with serotonin reuptake inhibitor activity. Bioorg Med Chem Lett 2007; 17:3130-5. [PMID: 17412583 DOI: 10.1016/j.bmcl.2007.03.034] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2007] [Accepted: 03/12/2007] [Indexed: 11/15/2022]
Abstract
The synthesis and structure-activity relationships of a series of novel phenoxyphenyl diamine derivatives with affinity for both the histamine H(3) receptor and the serotonin transporter is described.
Collapse
Affiliation(s)
- Emily M Stocking
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Narkhede S, Degani M. Pharmacophore Refinement and 3D-QSAR Studies of Histamine H3 Antagonists. ACTA ACUST UNITED AC 2007. [DOI: 10.1002/qsar.200610144] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
44
|
Amon M, Ligneau X, Camelin JC, Berrebi-Bertrand I, Schwartz JC, Stark H. Highly Potent Fluorescence-Tagged Nonimidazole Histamine H3 Receptor Ligands. ChemMedChem 2007; 2:708-16. [PMID: 17361979 DOI: 10.1002/cmdc.200600270] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Different (3-phenoxypropyl)piperidine derivatives have been coupled to fluorescent moieties (5-dimethylaminonaphthalene-1-sulfonyl, carbazol-9-ylcarbonyl, 2-cyanoisoindol-1-yl, 2-cyanobenzo[f]isoindol-1-yl, 2,4-dinitrobenzen-1-yl, 2,4-diaminophenyl, 7-nitrobenzofurazan-4-yl, 7-aminosulfonylbenzofurazan-4-yl, 4-methylcoumarin-6-yl) as novel histamine H(3) receptor ligands. They have been synthesised starting from piperidine in a few steps. The compounds display good to excellent histamine hH(3) receptor affinities with K(i) values ranging from 13.4 to 0.048 nM. Some of the new compounds belong to the most potent ligands known so far and may act as tools for identification and understanding of the binding site on the histamine H(3) receptor. In vivo screening on selected derivatives of Sanger's reagent showed antagonist potencies with ED(50) values from 7.9 to 0.39 mg kg(-1), p.o.
Collapse
Affiliation(s)
- Michael Amon
- Institut für Pharmazeutische Chemie, Johann Wolfgang Goethe-Universität, ZAFES/CMP, Biozentrum, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany
| | | | | | | | | | | |
Collapse
|
45
|
Keith JM, Gomez LA, Wolin RL, Barbier AJ, Wilson SJ, Boggs JD, Mazur C, Fraser IC, Lord B, Aluisio L, Lovenberg TW, Carruthers NI. Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors. Bioorg Med Chem Lett 2007; 17:2603-7. [PMID: 17317177 DOI: 10.1016/j.bmcl.2007.01.106] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2007] [Revised: 01/30/2007] [Accepted: 01/31/2007] [Indexed: 11/19/2022]
Abstract
A series of novel and potent pyrrolidino-tetrahydroisoquinolines with dual histamine H(3) antagonist/serotonin transporter inhibitor activity is described. A highly regio- and diastereoselective synthesis of the pyrrolidino-tetrahydroisoquinoline core involving acid mediated ring-closure of an acetophenone intermediate followed by reduction with NaCNBH(3) was developed. In vitro and in vivo data are discussed.
Collapse
Affiliation(s)
- John M Keith
- Johnson & Johnson Pharmaceutical Research and Development L.L.C., 3210 Merryfield Row, La Jolla, CA 92121, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Letavic MA, Keith JM, Ly KS, Barbier AJ, Boggs JD, Wilson SJ, Lord B, Lovenberg TW, Carruthers NI. Novel naphthyridines are histamine H3 antagonists and serotonin reuptake transporter inhibitors. Bioorg Med Chem Lett 2007; 17:2566-9. [PMID: 17307358 DOI: 10.1016/j.bmcl.2007.02.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2007] [Revised: 02/01/2007] [Accepted: 02/02/2007] [Indexed: 11/26/2022]
Abstract
A series of novel tetrahydronaphthyridine-based histamine H(3) ligands that have serotonin reuptake transporter inhibitor activity is described. The 1,2,3,4-tetrahydro-2,6-naphthyridine scaffold is assembled via the addition of a nitrostyrene to a metalated pyridine followed by reduction and cyclization to form the naphthyridine. In vitro biological data for these novel compounds are discussed.
Collapse
Affiliation(s)
- Michael A Letavic
- Johnson & Johnson Pharmaceutical Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121-1126, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Keith JM, Gomez LA, Letavic MA, Ly KS, Jablonowski JA, Seierstad M, Barbier AJ, Wilson SJ, Boggs JD, Fraser IC, Mazur C, Lovenberg TW, Carruthers NI. Dual serotonin transporter/histamine H3 ligands: Optimization of the H3 pharmacophore. Bioorg Med Chem Lett 2007; 17:702-6. [PMID: 17107798 DOI: 10.1016/j.bmcl.2006.10.089] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2006] [Revised: 10/26/2006] [Accepted: 10/26/2006] [Indexed: 10/24/2022]
Abstract
A series of tetrahydroisoquinolines acting as dual histamine H3/serotonin transporter ligands is described. A highly regio-selective synthesis of the tetrahydroisoquinoline core involving acid mediated ring-closure of an acetophenone intermediate followed by reduction with NaCNBH3 was developed. In vitro and in vivo data are discussed.
Collapse
Affiliation(s)
- John M Keith
- Johnson & Johnson Pharmaceutical Research and Development LLC, 3210 Merryfield Row, San Diego, CA 92121, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Letavic MA, Keith JM, Jablonowski JA, Stocking EM, Gomez LA, Ly KS, Miller JM, Barbier AJ, Bonaventure P, Boggs JD, Wilson SJ, Miller KL, Lord B, McAllister HM, Tognarelli DJ, Wu J, Abad MC, Schubert C, Lovenberg TW, Carruthers NI. Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorg Med Chem Lett 2007; 17:1047-51. [PMID: 17127059 DOI: 10.1016/j.bmcl.2006.11.036] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2006] [Revised: 11/07/2006] [Accepted: 11/10/2006] [Indexed: 10/23/2022]
Abstract
A series of novel 4-aryl-1,2,3,4-tetrahydroisoquinoline-based histamine H(3) ligands that also have serotonin reuptake transporter inhibitor activity is described. The synthesis, in vitro biological data, and select pharmacokinetic data for these novel compounds are discussed.
Collapse
Affiliation(s)
- Michael A Letavic
- Johnson & Johnson Pharmaceutical Research and Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Chapter 4 Recent Advances in Drug Discovery of Histamine H3 Antagonists. ANNUAL REPORTS IN MEDICINAL CHEMISTRY VOLUME 42 2007. [DOI: 10.1016/s0065-7743(07)42004-8] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
50
|
Abdel-Magid AF, Mehrman SJ. A Review on the Use of Sodium Triacetoxyborohydride in the Reductive Amination of Ketones and Aldehydes. Org Process Res Dev 2006. [DOI: 10.1021/op0601013] [Citation(s) in RCA: 336] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Ahmed F. Abdel-Magid
- Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Department of Chemical Development, Spring House, Pennsylvania 19477, U.S.A
| | - Steven J. Mehrman
- Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Department of Chemical Development, Spring House, Pennsylvania 19477, U.S.A
| |
Collapse
|